GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotech company focused on treating blood cancer. Its stock price is driven by news of clinical trials and partnerships. The chart reflects investor confidence in the potential of its drugs to become a new standard of care in their niche.
Share prices of companies in the market segment - Cancer blood
Syndax Pharmaceuticals is a biotechnology company focused on treating blood cancers. Its business consists of developing and commercializing its drugs. We classify it as part of the Cancer Blood sector, and the chart below reflects the dynamics of this entire biotechnology field.
Broad Market Index - GURU.Markets
Syndax Pharmaceuticals is an oncology company developing drugs to treat blood cancers, particularly leukemia. Its innovations earn it a spot in the GURU.Markets index. The chart below represents the market. See how clinical trial successes are impacting Syndax shares.
Change in the price of a company, segment, and market as a whole per day
SNDX - Daily change in the company's share price Syndax Pharmaceuticals
The daily price change of Syndax Pharmaceuticals, an oncology company, reflects the high risks of the biotech sector. Change_co is an immediate reaction to news about the clinical trials of its drugs. This indicator is the basis for analysis of the targeted cancer therapy sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer blood
Syndax Pharmaceuticals, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with SNDX's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Syndax is a biopharmaceutical company developing drugs to treat blood cancers. Oncology, particularly hematology, is a highly volatile sector. The chart below reflects average fluctuations in this industry, providing context for assessing the risks and potential of Syndax shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Syndax Pharmaceuticals
Syndax is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Annual dynamics of market capitalization of the market segment - Cancer blood
Syndax Pharmaceuticals, Inc. is a late-stage biotech company developing cancer treatments. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Syndax Pharmaceuticals is a late-stage biotech whose fate hinges on the approval and success of its cancer drugs. Its stock price is completely disconnected from economic cycles. Its chart is a history of binary events: positive regulatory news can trigger a surge, while negative news can cause a collapse.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Syndax Pharmaceuticals
The performance of Syndax, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its leukemia drugs, the success of which determines the company's entire future value, making the stock highly sensitive to research data.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development of treatments for hematological malignancies and solid tumors. Its sector dynamics, shown in the chart, reflect the R&D risks. Against this backdrop, it is possible to assess how progress in clinical trials of its leading drugs impacts the company's valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Syndax Pharmaceuticals is a biopharmaceutical company focused on treating blood cancers. Its value depends almost entirely on clinical trial results and regulatory approvals. Overall market performance has little impact on Syndax shares; their fate is decided in laboratories and FDA offices, which can lead to sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Syndax Pharmaceuticals
Syndax Pharmaceuticals, a biotech focused on blood cancer treatments, is experiencing high volatility. Weekly stock performance is driven by clinical trial data, regulatory decisions, and partnership news, reflecting the high stakes of oncology drug development.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Syndax Pharmaceuticals, like other biotech companies specializing in oncology, exhibits high volatility. The chart allows you to compare its performance with the sector to see how much of its movements are driven by general sentiment and how much by specific news about its drugs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Syndax Pharmaceuticals is a biotech company focused on treating blood cancer. Its shares follow their own rhythm, driven by clinical trial results. The chart shows how Syndax's performance is unaffected by general market fluctuations, relying on its own unique news.
Market capitalization of the company, segment and market as a whole
SNDX - Market capitalization of the company Syndax Pharmaceuticals
The Syndax Pharmaceuticals chart is a financial map of targeted oncology therapy. This biotech company's market cap reflects the hopes for its drugs, which target specific genetic mutations in leukemia and other cancers. Its dynamics are a barometer of progress in clinical trials and faith in the future of personalized medicine.
SNDX - Share of the company's market capitalization Syndax Pharmaceuticals within the market segment - Cancer blood
Syndax Pharmaceuticals is a biopharmaceutical company focused on developing treatments for hematological malignancies and solid tumors. Its sector market capitalization reflects the potential of its leading drug candidates. The chart below shows how the market views its chances in the fight against blood cancer.
Market capitalization of the market segment - Cancer blood
Syndax Pharmaceuticals is an oncology company targeting rare blood cancers. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investor expectations for the success of clinical trials and the development of new treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Syndax Pharmaceuticals is a biotech company focused on treating blood cancers. Its market capitalization chart is a financial bet on the success of its clinical programs. Its performance against the market tells the story of patient and investor hopes for new treatments for leukemia and lymphoma.
Book value capitalization of the company, segment and market as a whole
SNDX - Book value capitalization of the company Syndax Pharmaceuticals
For Syndax Pharmaceuticals, an oncology company, book value represents its clinical research capital. The chart below shows financial resources, not production capacity. Its growth reflects the company's investment in developing and testing new blood cancer drugs.
SNDX - Share of the company's book capitalization Syndax Pharmaceuticals within the market segment - Cancer blood
Syndax Pharmaceuticals is a biotech company focused on treating blood cancers. Its core capital is intellectual property. The share of physical assets will reflect its research-focused model, where its key assets are its high-tech laboratories.
Market segment balance sheet capitalization - Cancer blood
Syndax Pharmaceuticals is a biopharmaceutical company focused on treating blood cancer. Its assets are not plants, but rather clinical trial results and intellectual property. A book value chart will show how intangible its business is, as all its value is locked up in future drugs.
Book value of all companies included in the broad market index - GURU.Markets
Syndax Pharmaceuticals' assets are focused on fighting blood cancer. The company's book value reflects its investments in clinical research, development, and production of targeted drugs. The chart shows the size of its material and financial base dedicated to developing new treatments for leukemia and lymphoma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotech company developing drugs to treat blood cancers. Its book value is its cash reserves. Its market capitalization is the net valuation of its lead drug candidates and their chances of success in clinical trials. The chart reflects investors' faith in its science.
Market to book capitalization ratio in a market segment - Cancer blood
Syndax Pharmaceuticals is a biotech company specializing in blood cancer treatment. Its value is entirely dependent on the success of clinical trials. The chart shows how market expectations for its drugs compare to its minimal tangible assets. This is a pure bet on scientific success compared to other oncology startups.
Market to book capitalization ratio for the market as a whole
Syndax Pharmaceuticals is a biopharmaceutical company developing treatments for blood cancer. Its value depends almost entirely on the success of clinical trials and the potential of its drugs. The chart demonstrates how market valuation reflects investors' faith in science and future cash flows, rather than the company's current tangible assets.
Debts of the company, segment and market as a whole
SNDX - Company debts Syndax Pharmaceuticals
Syndax Pharmaceuticals, a company focused on treating blood cancer, uses debt to finance its clinical programs. This chart illustrates how it raises capital to conduct late-stage trials of its drug candidates. For a biotech without stable revenue, debt financing is a bridge to potential approval and commercial success.
Market segment debts - Cancer blood
Syndax Pharmaceuticals is a biopharmaceutical company focused on treating blood cancers. Drug development is a long and expensive process, and companies in this sector often use a combination of equity and debt to finance trials. The chart shows how Syndax manages its finances on the path to potential drug approval.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotech company focused on developing treatments for blood cancer. Its survival and success depend on the results of clinical trials. This chart shows its financing policy. Having little or no debt is critical, as it allows the company to weather potential research setbacks without risking bankruptcy.
Market segment debt to market segment book capitalization - Cancer blood
Syndax Pharmaceuticals is a biopharmaceutical company developing treatments for hematological malignancies (blood cancers). This is a complex and competitive field of oncology. This chart shows the overall debt burden in the pharmaceutical industry. It provides context for assessing Syndax's financial strategy during its long clinical development journey.
Debt to book value of all companies in the market
Syndax Pharmaceuticals, an oncology biotech, requires massive capital investment. This chart shows the overall market leverage, reflecting risk appetite. It helps understand how investor sentiment fluctuates and how easily companies like Syndax can raise capital for their risky projects during different phases of the economic cycle.
P/E of the company, segment and market as a whole
P/E - Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotech company focused on treating blood cancers. This chart reflects investor expectations for its leading drug candidates. Its value is directly dependent on clinical trial results and regulatory decisions. Success in trials can lead to explosive growth, while failure can lead to a sharp decline.
P/E of the market segment - Cancer blood
Syndax Pharmaceuticals is a biotech company operating in the oncology sector. This chart shows the industry's average P/E, which is full of promise. Comparing the company's P/E to this benchmark allows us to judge how highly the market values its blood cancer drug candidates compared to the average prospects of other biotechs.
P/E of the market as a whole
Syndax Pharmaceuticals is a biotech company specializing in blood cancer treatment. Its value depends almost entirely on the success of its clinical programs and regulatory approvals. This chart shows investors' overall risk appetite. It helps understand whether Syndax's valuation is a response to specific scientific data or is moving in line with the broader biotech sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotech company focused on the treatment of oncology, particularly blood cancers. This chart reflects investor expectations for clinical trials and potential approval of its drugs. The company's valuation is based on forecasts of future commercial success for its developments in the fight against leukemia and lymphoma.
%20P%2FE%20Syndax%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Syndax-Pharmaceuticals&v=1772659548613 "Chart of the company's future (projected) P/E Syndax Pharmaceuticals")
Future (projected) P/E of the market segment - Cancer blood
Syndax Pharmaceuticals is focused on developing drugs for blood cancers such as leukemia. This chart compares the company's future profitability expectations with the oncology sector. It shows how optimistic investors are about its clinical developments and their potential to become a new standard of care in its niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772659548616 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Syndax Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for blood cancer. Like many biotech companies, its success depends on clinical trial results and the availability of funding. This chart, reflecting overall market optimism, influences investor willingness to invest in high-risk but potentially breakthrough scientific projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772659548620 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biopharmaceutical company developing cancer treatments. Its financial health depends on the success of clinical trials and partnerships with larger pharmaceutical companies. This chart illustrates a typical biotech scenario: significant investments in R&D drive operating expenses in anticipation of future revenues from drug commercialization.
Profit of companies in the market segment - Cancer blood
Syndax Pharmaceuticals is a biotech company developing drugs to treat oncology, particularly blood cancers. This chart, showing the overall sector returns, reflects the high risks and potential rewards of biotech. Success in Syndax's clinical trials could not only change the standard of care but also drive significant growth across the entire hematology-oncology niche.
Overall market profit
Syndax Pharmaceuticals is focused on developing drugs for blood cancers. Biotech companies in this field thrive on clinical trials and scientific discoveries. Their value is determined not by economic conditions, but by the potential to save lives. Syndax exemplifies how investing in science can lead to breakthroughs that transform medicine and patients' lives.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biopharmaceutical company specializing in the treatment of blood cancers. The future profit projections you see are directly dependent on the success of its clinical programs and the potential approval of new drugs. This chart reflects analyst expectations regarding the commercial potential of the drugs in development.
%20profit%20of%20the%20company%20Syndax%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Syndax-Pharmaceuticals&v=1772659548635 "Graph of future (projected) profit of the company Syndax Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Cancer blood
Syndax Pharmaceuticals is a biopharmaceutical company focused on developing treatments for hematological malignancies (blood cancers). This chart shows revenue forecasts for this specific oncology segment. It reflects analysts' expectations for breakthroughs in leukemia and lymphoma treatments, and how Syndax might fit into them.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772659548637 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Syndax Pharmaceuticals is a biotech company developing treatments for blood cancer. Its shares react more to news about clinical trials than to macroeconomic data. However, the overall market sentiment reflected in this chart influences the entire biotech sector. Increased risk appetite makes it easier to raise capital for further research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772659548638 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotech company specializing in the development of treatments for blood cancers. This metric, which correlates market capitalization with revenue (if any), reflects investor expectations. It suggests a premium valuation based not on current sales, but on the potential of its drugs, which are in various stages of clinical trials.
P/S market segment - Cancer blood
Syndax Pharmaceuticals is a biotechnology company specializing in the development of treatments for hematological malignancies (blood cancers). Its portfolio includes innovative drug candidates. This chart shows how investors value revenue in the oncology niche, helping to understand the market's confidence in the scientific potential and future commercial success of Syndax's drugs.
P/S of the market as a whole
Syndax Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for hematological malignancies and solid tumors. Its valuation is dependent on the success of its clinical programs. This chart, showing average revenue estimates, provides insight into how the market values biotech companies in the R&D stage.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biopharmaceutical company developing drugs to treat oncological blood diseases. For a development-stage company, this chart shows the market's assessment of its potential future revenue from drug commercialization. It reflects investor confidence in the success of clinical trials and the demand for its targeted therapies.
%20P%2FS%20Syndax%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Syndax-Pharmaceuticals&v=1772659548653 "The graph of the company's future (projected) P/S Syndax Pharmaceuticals")
Future (projected) P/S of the market segment - Cancer blood
Syndax Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for hematological malignancies (blood cancers). This chart compares investor expectations for its future revenue with the sector. A high valuation indicates high hopes for its key drugs in development, while a more conservative valuation reflects the risks of clinical trials and competition.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772659548657 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Syndax Pharmaceuticals is a biotech company specializing in the development of treatments for blood cancer. Its financial future depends entirely on the success of clinical trials and regulatory approvals. This market expectations chart provides an overview of investor sentiment toward high-risk but potentially disruptive companies in the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772659548659 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Syndax Pharmaceuticals
Syndax Pharmaceuticals' revenue growth reflects progress in cancer drug development. As the company is in the clinical stage, its revenue is generated not from direct sales, but from licensing agreements and milestone payments from partners. This growth reflects successful achievement of key clinical trial milestones.
Sales of companies in the market segment - Cancer blood
Syndax Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for blood cancers and solid tumors. The company's portfolio focuses on innovative drug combinations. This chart represents the total revenue of the entire oncology drug market, demonstrating the commercial potential that Syndax is targeting with its developments.
Overall market sales
Syndax Pharmaceuticals is a biotech company focused on treating blood cancers. Its success depends on clinical trial results and drug approvals. This sector isn't directly affected by economic cycles, but the overall situation shown in this chart influences public and private healthcare funding, which is important for the commercialization of new drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotechnology company specializing in the development of treatments for blood cancers and solid tumors. Future revenue depends on the success of clinical trials and regulatory approvals of its drugs. This chart represents analysts' long-term forecast based on the scientific and commercial potential of its oncology portfolio.
%20sales%20of%20the%20company%20Syndax%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Syndax-Pharmaceuticals&v=1772659548672 "Schedule of future (projected) sales of the company Syndax Pharmaceuticals")
Future (projected) sales of companies in the market segment - Cancer blood
Syndax Pharmaceuticals is a biopharmaceutical company specializing in the treatment of blood cancers. This chart displays projected revenues for its drugs in development and those already on the market. The data shows how analysts assess the commercial potential of each drug in the company's portfolio and its ability to fill its niche in oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772659548676 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
The biotech investment climate, reflected in this chart, is critical for Syndax Pharmaceuticals. The company, focused on treating blood cancers, relies on research funding. Capital inflows into the industry increase with positive economic forecasts, allowing companies like Syndax to advance their research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772659548699 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Syndax Pharmaceuticals
Syndax Pharmaceuticals is a clinical-stage biotechnology company focused on developing cancer treatments. This chart reflects its current status as a research investment platform. Profitability is a future goal, dependent on successful clinical trial results and regulatory approval of its targeted therapies.
Market segment marginality - Cancer blood
Syndax Pharmaceuticals is a biotechnology company specializing in the development of drugs to treat blood cancers such as leukemia and lymphoma. Its profitability depends on the success of clinical trials and the subsequent commercialization of its targeted therapies. This chart shows the average profitability in the pharmaceutical industry, providing context for assessing the potential of Syndax's developments.
Market marginality as a whole
Syndax Pharmaceuticals is a biopharmaceutical company developing treatments for blood cancer. Its market capitalization and success depend on clinical trial results and its ability to raise capital. This chart reflects the overall investment climate. During favorable economic periods, investors are more willing to fund risky but promising biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotech company developing treatments for blood cancers. This chart reflects the size of the team of scientists and clinicians advancing drugs through the development stages. Growth on the chart indicates progress in clinical programs and preparation for potential commercialization, a key milestone for any biotech company.
Share of the company's employees Syndax Pharmaceuticals within the market segment - Cancer blood
Syndax Pharmaceuticals is focused on developing innovative treatments for blood cancers and solid tumors. Its core asset is its team of scientists and clinicians. This chart shows the percentage of all researchers in its narrow therapeutic area that Syndax represents. This reflects the depth of its scientific expertise and the potential of its drugs.
Number of employees in the market segment - Cancer blood
Syndax Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of oncological diseases, particularly blood cancers. The chart illustrates employment in the hematological oncology sector. The growing number of scientists and clinicians in this field indicates intensive research and development of new targeted therapies, a key focus for Syndax.
Number of employees in the market as a whole
Syndax Pharmaceuticals is a biotechnology company specializing in the treatment of blood cancers. Their success depends entirely on scientific developments and clinical trial results. This general employment schedule has no bearing on their operational activities. The hiring of scientists and clinicians at Syndax is determined by progress in the fight against oncology.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals is a biopharmaceutical company specializing in blood cancer treatment. Its value is determined by its scientific portfolio. This chart shows how the market values the potential of its drug candidates. A relatively small team of scientists creates intellectual property with the potential to be worth billions of dollars.
%20of%20the%20company%20Syndax%20Pharmaceuticals%20(SNDX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Syndax-Pharmaceuticals-SNDX&v=1772659548751 "Chart of market capitalization per employee (in thousands of dollars) of the company Syndax Pharmaceuticals (SNDX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Syndax Pharmaceuticals is a biotech company specializing in blood cancer treatment. Like other companies in the sector, their value lies in their R&D pipeline and drug intellectual property. This chart reflects the high market value that investors attribute to their scientific potential.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772659548762 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Syndax Pharmaceuticals is a biotech company specializing in blood cancer treatment. Its market capitalization is directly dependent on the progress of clinical trials and the commercial potential of the drugs being developed. This chart illustrates how, in biotech, a small team of scientists and managers can create intellectual property worth hundreds of millions or even billions of dollars.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772659548764 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals is a clinical-stage biotech company focused on treating blood cancers (leukemia and lymphoma). This chart isn't about profit, but about the R&D "burn rate": it shows how much the company spends (negative profit) on each employee (scientist, physician) to conduct expensive clinical trials.
%20Chart%20Syndax%20Pharmaceuticals%20(SNDX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Syndax-Pharmaceuticals-SNDX&v=1772659548767 "Company Profit Per Employee (in thousands of dollars) Chart Syndax Pharmaceuticals (SNDX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Syndax Pharmaceuticals is a clinical-stage biotech company developing a targeted therapy for the treatment of blood cancer (leukemia). This chart shows the benchmark for the "Biotech" sector. In this industry, the average profit per employee is typically deeply negative. The benchmark is determined not by "profit," but by the "burn rate" of the R&D budget.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772659548776 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Syndax Pharmaceuticals is a biotech company focused on cancer treatment, particularly blood cancer (leukemia). Their core business is clinical trials and the discovery of new molecules. All value is created in the lab and during testing. This chart helps us understand how the biotech R&D model, with its small team of scientists, differs from the market in terms of staff efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772659548782 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals is a biopharmaceutical company specializing in the treatment of blood cancers. Because its drugs are in late stages of development, revenue per employee may be minimal and come from partnerships. This graph reflects the current R&D phase, and its future growth will depend on the commercial success of approved drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Syndax-Pharmaceuticals-SNDX&v=1772659548794 "Sales chart per company employee Syndax Pharmaceuticals (SNDX)")
Sales per employee in the market segment - Cancer blood
Syndax Pharmaceuticals is a biotech company focused on cancer treatment, particularly blood cancers. Their strategy is to develop targeted and immune-based therapies. This is an R&D business. This chart shows their stage of maturity. Revenue, if any, likely comes from partnerships, while the productivity of their scientific team is focused on future FDA approvals.
Sales per employee for the market as a whole
Syndax Pharmaceuticals (SNDX) is a biotech company specializing in cancer treatment, specifically drugs targeting specific genetic mutations (such as those found in leukemia). This is a leading oncology company. This chart reflects the economics of clinical-stage biotech. Revenue (if any) comes from partnerships, not sales. The company's entire scientific staff is focused on R&D, and this metric reflects the intensity of its investment.
Short shares by company, segment and market as a whole
Shares shorted by company Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals is a biotech company focused on cancer treatment, particularly leukemia. Their strategy includes developing targeted therapies and checkpoint inhibitors. This chart shows the number of bearish bets. Bearish bets may doubt the success of their key candidates in clinical trials or point to the high risk and long road to approval and commercialization in the crowded oncology field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Syndax-Pharmaceuticals-SNDX&v=1772659548811 "Short Shares Chart for the Company Syndax Pharmaceuticals (SNDX)")
Shares shorted by market segment - Cancer blood
Syndax Pharmaceuticals (SNDX) is a biopharmaceutical company specializing in the treatment of blood cancers (leukemia and lymphoma). They focus on targeted therapies. This chart reflects bets against the oncology sector. Investors shorting this segment may be concerned about regulatory risks or intense competition, with many companies working on similar treatments.
Shares shorted by the overall market
Syndax (SNDX) is a clinical-stage biotech (oncology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives SNDX of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals is a biotech company focused on treating blood cancers (leukemia, lymphoma). Their success depends on the approval of their targeted drugs. This chart measures the level of speculative interest. It shows when the stock is "overbought" due to positive clinical trial data or "oversold" due to news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Syndax-Pharmaceuticals-SNDX&v=1772659548831 "RSI 14 indicator chart for the company's stock Syndax Pharmaceuticals (SNDX)")
RSI 14 Market Segment - Cancer blood
Syndax Pharmaceuticals is a biotech company focused on developing drugs to treat blood cancers (hematological oncology), particularly leukemia. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated by expectations of clinical success.
RSI 14 for the overall market
Syndax Pharmaceuticals (SNDX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SNDX (Syndax Pharmaceuticals)
Syndax Pharmaceuticals is a biotech company focused on developing drugs to treat blood cancers such as leukemia and lymphoma. This chart shows the average analyst forecast. Their targets are based on the likelihood of success of key drugs in clinical trials and the potential market size for them.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SNDX-Syndax-Pharmaceuticals&v=1772659548888 "A chart showing analyst consensus forecasts for the expected stock price. SNDX (Syndax Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price SNDX (Syndax Pharmaceuticals)
Syndax (SNDX) is an oncology company developing a targeted therapy (revumenib) for the treatment of rare forms of acute leukemia. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their lead drug candidate for the treatment of blood cancers.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SNDX-Syndax-Pharmaceuticals&v=1772659548900 "A chart showing the difference between the consensus forecast and the actual stock price. SNDX (Syndax Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Syndax Pharmaceuticals is an oncology company with two promising drugs in late-stage development: one for leukemia and the other for graft-versus-host disease. This chart shows overall expectations for the blood cancer sector, reflecting whether experts believe these drugs will be approved soon.
Analysts' consensus forecast for the overall market share price
Syndax Pharmaceuticals (SNDX) is an R&D biotech focused on oncology (blood cancer, leukemia). They're burning through cash. This chart, reflecting expert expectations, is their risk appetite. When the market is pessimistic, investors flee cash-burning, pre-profit biotechs, even those with good science.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Syndax Pharmaceuticals
Syndax is a biotech company focused on targeted cancer therapy. Their main asset (revumenib) is a breakthrough drug for the treatment of specific types of leukemia. This chart is a pure indicator of their R&D pipeline. It likely aggregates their clinical trial data, assessment of the market potential of their drugs, and confidence in their scientific approach.
AKIMA Market Segment Index - Cancer blood
Syndax (SNDX) is a clinical-stage biotech focused on oncology, developing innovative drugs (Revumenib) for the treatment of rare and aggressive blood cancers (leukemia). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D focus on blood cancer (SNDX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Syndax Pharmaceuticals is a biotech company developing targeted therapies for leukemia and solid tumors. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story, approaching commercialization, fits in with the overall economic trends affecting biotech.
